Table 1.

Overview of Commercial Preventive HPV Vaccines.

	Gardasil	Cervarix
Manufacturer	Merck	GlaxoSmithKline
HPV types	16, 18, 6, 11	16, 18
Amount of HPV L1 protein	20 μg HPV-6 40 μg HPV-11 40 μg HPV-16 20 μg HPV-18	20 μg HPV-16 20 μg HPV-18
Adjuvant	225 μg aluminum hydroxyphosphate sulfate	AS04 composed of: 500 μg aluminum hydroxide 50 μg MPL (3-O-desacyl-4′-monophosphoryl lipid A)
FDA Approval in US	June 2006	October 2009
Regimen	3 doses: Months 0, 2, 6	3 doses: Months 0, 1, 6
Cost	$120 USD per dose	$100 USD per dose
Antigen Source	Saccharomyces cerevisiae (bread yeast), expressing L1	Trichoplusia ni insect cell line infected with L1 encoding recombinant baculovirus
Indications	Girls and young women: age 9 – 26 For the prevention of cervical, vulvar, vaginal cancer, and anal cancer and associated pre-cancerous lesions and genital warts Boys and young men: ages 9 – 26 For the prevention of anal cancer and associated pre-cancerous lesions, and genital warts	Girls and young women: age 10 – 25 For the prevention of cervical cancer and associated pre-cancerous lesions
Duration of protection	At least 6.4 years [60,61]	At least 8.4 years [40,63]
Antibody titers	HPV-16: 2.3 – 4.8 times higher for Cervarix compared with Gardasil, across all age groups HPV-18: 6.8 – 9.1 times higher with Cervarix [64]